GlobeNewswire by notified

Elanders makes another acquisition and strengthens its offer in Life Cycle Management and Technical Logistics in the UK

Share

Today, Elanders acquired all the shares in Bonds World Wide Holdings Limited with its subsidiaries Bonds World Wide Express Limited and Bonds Technical Couriers Limited (together “Bonds”). Bonds is a leading actor in the UK within special transportation and installation of advanced technical equipment. The company is privately owned and had net sales of some GBP 5 million in 2021 with good profitability.

In line with Elanders’ strategy of investment and growth in the Life Cycle Management area, Elanders has today signed a contract to acquire all the shares in the technical logistics company Bonds World Wide Holdings Limited. Bonds is located in Birmingham and is a major player in the technical equipment transport industry in the United Kingdom. Bonds offers an extensive range of services, including the assembly and installation of advanced technical equipment. They do this for the IT industry as well as for ITAD (IT Asset Disposition) providers, the medical sector and the retail industry.

As a result of the acquisition, Elanders will be able to offer unique solutions for special transportation, and installation and recovery of advanced technical equipment. The acquisition is also a step in increasing the proportion of value-adding services, particularly to customers in Electronics and Healthcare & Life Science. Bonds will become part of the business area Supply Chain Solutions and be a subsidiary to Elanders’ subgroup LGI.

“We are convinced that we will work in great synergy with the team at Bonds, as we share the same passion for high-tech logistics. The acquisition of Bonds will further strengthen Elanders’ international footprint and brings good synergies with the existing activities in the UK”, says Bernd Schwenger, CEO and President of LGI.

Bonds will be consolidated into the Elanders Group as of 1 July 2022. The purchase price is approximately GBP 5 million on a cash- and debt-free basis, if IFRS 16 effects are excluded from the debt. The major part of the purchase price will be paid in the third quarter. The acquisition is financed through existing credit facilities and the acquisition cost is estimated to be less than SEK 2 million.

For further questions, please contact
Magnus Nilsson, President and CEO, telephone: +46 31 750 07 50
Andréas Wikner, CFO, telephone: +46 31 750 07 50

This information is information that Elanders AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 11:30 CET on 1 July 2022.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Sodexo announces solid H1 Fiscal 2024 results19.4.2024 07:00:00 CEST | Press release

Issy-les-Moulineaux, April 19, 2024 Sodexo (Euronext Paris FR 0000121220-OTC: SDXAY) Sodexo announces solid H1 Fiscal 2024 results Organic Revenue growth +8.5%Underlying operating profit +16.9% at constant currencies, margin up +40 bpsFiscal 2024 guidance:Organic growth now expected at the top of the +6% to +8% rangeUnderlying operating profit margin improvement confirmed at +30 to +40 bps, at constant currencies At the Board of Directors meeting held on April 18, 2024, chaired by Sophie Bellon, the Board closed the Consolidated accounts for the First half Fiscal 2024 ended February 29, 2024. First half Fiscal 2024 key figures (in million euros)H1 FISCAL 2024H1 FISCAL 2023 RESTATEDDIFFERENCEDIFFERENCE CONSTANT RATESRevenues12,10111,581 +4.5% +7.8%Organic revenue growth +8.5% +12.9%UNDERLYING OPERATING PROFIT612545+12.3%+16.9%UNDERLYING OPERATING PROFIT MARGIN5.1%4.7%+40bps+40bpsOther operating income & expenses30(36)OPERATING PROFIT642509+26.1%+30.1%Net financial expense(46)(43)Tax cha

Pluxee delivers strong performance in the First Half and raises Fiscal 2024 Organic revenue growth and Recurring EBITDA margin objectives19.4.2024 07:00:00 CEST | Press release

First Half Fiscal 2024 Results Issy-les-Moulineaux, France – April 19, 2024 First Half Fiscal 2024 highlights Successful spin-off and listing on Euronext Paris on February 1, 2024 Organic revenue growth of +24% incl. +26% in Q2, reflecting buoyant performance across all regions Strong Recurring EBITDA at €201 million, i.e. +28% organic growth; 34.4% margin at constant rates Net profit of €68 million reflecting higher one-time items, mostly spin-off related Recurring free cash flow of €228 million, with strong Recurring Cash conversion of 113%Net cash position of €1,065 million, increasing by €206 million since August 31, 2023Fiscal 2024 financial objectives raised: Organic revenue growth expected between 15% to 17% and Recurring EBITDA margin expected at 35% at least including standalone costs at constant rates, while reaffirming all mid-term targets First Half Fiscal 2024 key figures (in millions of euros)H1 FY 2024H1 FY 2023Variation (%)Variation at constant rate (%)Total revenues593

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer19.4.2024 07:00:00 CEST | Press release

Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2The National Comprehensive Cancer Network® (NCCN®) Guidelines recommend routine testing for ALK, EGFR and PD-L1 biomarkers in people with early-stage NSCLC to inform adjuvant therapy selection Basel, 19 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumours ≥ 4 cm or node positive), as detected by an FDA-approved test. Alecensa is now the first and on

Evs Invites Its Shareholders to the Ordinary General Meeting and an Extraordinary General Meeting on May 21, 202419.4.2024 06:30:00 CEST | Press release

Publication on April 19, 2024, at 6:30 am before market opening Regulated information EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS INVITES ITS SHAREHOLDERS TO THE ORDINARY GENERAL MEETING AND AN EXTRAORDINARY GENERAL MEETING ON MAY 21, 2024 EVS Broadcast Equipment, leading provider of live video production systems, published today the invitation to its Ordinary General Meeting, to be held on May 21, 2024, at 11 am, at its registered office in Liège, to deliberate on the agenda available on the website of the company (see link below). Aside from the usual topics, including the 2023 annual and sustainability reports, the Board of Directors will propose to the Shareholders to approve the following resolutions: The payment of a total gross dividend of EUR 1.10 per share (including the interim dividend of EUR 0.50 paid in November 2023);A profit-sharing plan in the form of a grant of 36 EVS shares for each EVS employee, in proportion to

Icelandic Salmon - Annual Report for 202319.4.2024 06:00:00 CEST | Press release

Bíldudalur, 19 April 2023 Icelandic Salmon AS (Euronext Growth Oslo and First North Iceland: ISLAX) has today published its integrated Annual Report for 2023, including sustainability reporting and complete annual accounts with notes. The report is attached and available on the company‘s website: https://arnarlax.is/investors/ “In 2023, Icelandic Salmon supplied the world markets with a record-breaking 17,919 tonnes of salmon, thanks to the dedicated work of our employees. Despite facing many challenges this year - including macroeconomic changes, geopolitical tensions, and biological obstacles – we prioritised the health and wellbeing of our fish. Looking ahead, we are committed to sustaining this priority while growing our operations," Bjørn Hembre, CEO of Icelandic Salmon and Arnarlax says. In Bjørn‘s letter, which in included in the report, he writes: “Salmon farming holds great promise for Iceland, in terms of future jobs and economic growth. During the past few years, we have see

HiddenA line styled icon from Orion Icon Library.Eye